The development of effective biomarkers for Alzheimer's disease: a review
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Objective: There is a widely recognised need to develop effective Alzheimer's disease (AD) biomarkers to aid the development of disease‐modifying treatments, to facilitate early diagnosis and to improve clinical care. This overview aims to summarise the utility of key neuroimaging and cerebrospinal fluid (CSF) biomarkers for AD, before focusing on the latest efforts to identify informative blood biomarkers. Design: A literature search was performed using PubMed up to September 2011 for reviews and primary research studies of neuroimaging (magnetic resonance imaging, magnetic resonance spectroscopy, positron emission tomography and amyloid imaging), CSF and blood‐based (plasma, serum and platelet) biomarkers in AD and mild cognitive impairment. Citations within individual articles were examined to identify additional studies relevant to this review. Results: Evidence of AD biomarker potential was available for imaging techniques reflecting amyloid burden and neurodegeneration. Several CSF measures are promising, including 42 amino acid β‐amyloid peptide (A β42); total tau (T‐tau) protein, reflecting axonal damage; and phosphorylated tau (P‐tau), reflecting neurofibrillary tangle pathology. Studies of plasma A β have produced inferior diagnostic discrimination. Alternative plasma and platelet measures are described, which represent potential avenues for future research. Conclusions: Several imaging and CSF markers demonstrate utility in predicting AD progression and determining aetiology. These require standardisation before forming core elements of diagnostic criteria. The enormous potential available for identifying a minimally‐invasive, easily‐accessible blood measure as an effective AD biomarker currently remains unfulfilled. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Clusterin gene polymorphism associates with increased risk for late-onset AD (Harold et al., 2009).”
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“One 6-year MCI study combined CSF biomarkers, demonstrating prediction of AD with a sensitivity of 95% and a specificity of ~85% using either T-tau and Ab42, or a combination of T-tau and Ab42/ P-tau181 ratio (Hansson et al., 2006).”
MethodMitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 1×
“A recent meta-analysis concluded that, for memory clinic attendees with subjective memory complaints fulfilling an MCI diagnosis, the risk of progression to dementia was 9.6% per year (Mitchell and Shiri-Feshki, 2009).”
MethodInfluentialCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“To date, around 50 studies, involving a total of 5000 patients and controls, have demonstrated threefold increases in CSF T-tau in AD patients compared with controls (Blennow and Hampel, 2003; Hampel et al., 2008).”
ResultCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“This work initially yielded a panel of 18 proteins with reported diagnostic accuracy of 90% for AD and 81% for MCI subjects who progressed to AD over 7 years (Ray et al., 2007).”
BackgroundJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Neuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825 · cited 1×
“…diagnosis of probable AD can only be confirmed post-mortem by histopathological identification of amyloid plaques, containing a core of b-amyloid (Ab) peptide, and neurofibrillary tangles (NFT) of abnormally phosphorylated microtubule-associated tau protein (Maccioni et al., 2001; Perl, 2010).”
Background
Cited by
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
“While it is well accepted that the CSF mirrors neurochemical changes in the AD brain [1], the precise degree of overlap between the AD brain and CSF is unclear.”
BackgroundHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
“These techniques focused on t neuronal injury and degeneration aspects of AD [1].”
BackgroundMethodInfluentialMulti-modal classification of Alzheimer's disease using nonlinear graph fusion
Tong, T., Gray, K., Gao, Q., Chen, L., & Rueckert, D. (2017) · Pattern Recognition · doi:10.1016/j.patcog.2016.10.009 · Cited by 258
Tang, W., Huang, Q., Wang, Y., Wang, Z.-Y., & Yao, Y.-Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.015 · Cited by 38
Metadata
- Authors
- Henry, M. S., Passmore, A. P., Todd, S., McGuinness, B., Craig, D., & Johnston, J. A.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2012-06-04
- Volume
- 28
- Issue
- 4
- Pages
- 331-340
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1563543424
- Cited by
- 49
- References
- 40
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The development of effective biomarkers for Alzheimer's disease: a review. https://app.cochat.ai/papers/10.1002/gps.3829
- The paper
- Henry, M. S., Passmore, A. P., Todd, S., McGuinness, B., Craig, D., & Johnston, J. A. (2013). The development of effective biomarkers for Alzheimer's disease: a review. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.3829
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.